Detalhe da pesquisa
1.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood;
142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37441846
2.
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
Cancer;
2024 Jun 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38896064
3.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer;
129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36458426
4.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol;
98(10): E281-E284, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37515433
5.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol;
98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37665752
6.
Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency.
Mycoses;
66(12): 1029-1034, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37550272
7.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta Haematol;
145(5): 529-536, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35717939
8.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Br J Haematol;
195(3): 378-387, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34340254
9.
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Am J Hematol;
95(11): 1399-1420, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32744763
10.
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Hematol Oncol;
37(1): 96-102, 2019 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30153704
11.
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Am J Hematol;
96(7): E246-E249, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33811786
12.
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Am J Hematol;
95(12): E326-E329, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32886803
13.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Cancer Med;
13(5): e7093, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38497538
14.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Blood Adv;
8(11): 2695-2706, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38513082
15.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Clin Cancer Res;
30(7): 1319-1326, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38300723
16.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
J Clin Oncol;
42(13): 1499-1508, 2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38277619
17.
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Blood Adv;
7(19): 5691-5697, 2023 10 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36696472
18.
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leuk Lymphoma;
63(13): 3154-3164, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36059252
19.
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.
Biology (Basel);
12(1)2022 Dec 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36671709
20.
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Exp Hematol;
115: 44-53, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36150563